According to the Zhitong Finance App, Libang Pharmaceutical-B (09637) announced that according to Hong Kong Stock Connect's relevant arrangements and adjustments, the company's H shares have been included in the Hong Kong Stock Connect Eligible Securities List and will take effect from September 7, 2026 (Monday). From the effective date, eligible investors in mainland China can directly trade H shares through the relevant mechanisms of the Hong Kong Stock Connect.

H shares were included in the Hong Kong Stock Connect based on their inclusion in the Hang Seng Composite Index. According to the results of the Hang Seng Index series of quarterly reviews up to June 30, 2026 announced by Hang Seng Index Limited on August 21, 2026, H shares were included as constituent stocks of the Hang Seng Composite Index. The relevant changes were implemented after the market closed on September 4, 2026 (Friday), and will take effect from September 7, 2026 (Monday).

The board of directors believes that the inclusion of H shares in the Hong Kong Stock Connect and Hang Seng Composite Index reflects the capital market's recognition of the company's value and long-term development prospects, and will help further expand the company's investor base and enhance the trading liquidity of H shares.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.